via UBC
A new study shows that a single corporation has registered nearly half of all existing gene patents from marine organisms
A single corporation has registered nearly half of all existing patents associated with genes from marine organisms, according to a new study. Researchers from the University of British Columbia and the Stockholm Resilience Centre examined the patents associated with marine species and found that BASF, the world’s largest chemical manufacturer, has registered 47 per cent of the 12,998 genetic sequences from 862 marine species.
The holder of a gene patent decides how the gene can be used in commercial and noncommercial settings including research. The unique genetic adaptations of marine organisms, which have evolved to thrive in various ocean environments, make them particularly attractive to commercial enterprises. Of the top 30 largest patent owners, who accounted for 84 per cent of patents, all but five were corporate entities. Public and private universities accounted for 12 per cent, while governmental agencies, individuals, hospitals, and non-profit research institutes registered four per cent. Overall, entities located in just 10 countries accounted for 98 per cent of the patents, according to the study published in Science Advances.
“By 2025, the global market for marine biotechnology is expected to reach $6.4 billion and span a broad range of commercial purposes for pharmaceutical, biofuel, and chemical industries,” said Colette Wabnitz, research associate in the UBC Institute for the Oceans and Fisheries, and co-author on the study.
While countries are protected from exploitative bioprospecting, meaning the search for commercially-valuable compounds from nature, by The Nagoya Protocol on Access to Genetic Resources and the Fair and Equitable Sharing of Benefits Arising from their Utilization to the Convention on Biological Diversity, two-thirds of the Earth’s surface exists beyond national jurisdiction. A considerable portion of all patent sequences (11 per cent) are derived from species associated with deep sea and hydrothermal vent ecosystems, many of which are found in these unregulated areas.
“Roughly half of the Earth’s surface is left with no regulations on accessing or using genetic resources,” said Robert Blasiak, fellow at the Stockholm Resilience Centre and first author on the study. “Establishing a legal framework for marine genetic resources will be a core issue when international negotiations on a new UN treaty on the conservation and sustainable use of biodiversity in areas beyond national jurisdiction (BBNJ) begin in earnest in September 2018.”
Countries that are signatories to the United Nations Convention on the Law of the Sea (UNCLOS) have committed to promoting the development and transfer of marine technology, a commitment that may have implications in the upcoming negotiations. Of the 30 countries involved in patenting these resources, 27 are parties to UNCLOS.
“Equity is deeply embedded within UNCLOS and the language of the Sustainable Development Goals,” said Wabnitz. “Ensuring that the process moves forward in an inclusive manner means that states should increase their commitments to disclose the geographic origin of marine genetic resources, and promote greater international participation in discovering and using the benefits of marine biodiversity.”
The authors note that the existence of a handful of corporations with a disproportionate influence also suggests an opening for more direct engagement with them. “It is clear that these industry leaders must be involved in the upcoming BBNJ treaty negotiations, if only by virtue of their ownership of such a large share of the marine genetic sequence patents,” said Wabnitz. “Such engagement could help companies distinguish themselves through their proactive behaviour and contribute to providing new norms and standards associated with transparency, capacity building, and benefit sharing.”
The study, “Corporate control and global governance of marine genetic resources” was published in Science Advances.
Background:
Researchers created a database of 38 million sequences of genetic material associated with patents by accessing the publicly available records of the PAT division of GenBank from the National Center for Biotechnology Information.
Records of patent sequences from 862 marine species were extracted from the database and analyzed with regard to patent applicants. In total, 12,998 relevant sequences were found to be registered by a total of 559 entities.
Information collected on the applicants led to their subsequent classification into three broad categories: companies, universities and their commercialization centres, and others (national institute or agency or government body, individuals, hospitals, nonprofit research institutes).
Sequences from a wide range of species have been associated with patents, from the sperm whale (Physeter macrocephalus) and giant oceanic manta ray (Manta birostris) to microscopic archaea and plankton.
Supplementary material for this article is available here.
Learn more: Vast majority of patents on marine genetic sequences linked to corporations
The Latest on: Gene patents
via Google News
The Latest on: Gene patents
- TAU Researchers Find Common Gene Mutation Mechanism in Autism, Schizophreniaon May 24, 2022 at 1:21 am
An experimental drug developed at a TAU lab may be suitable for treating a range of rare syndromes that impair brain functions.
- Day One of Patent Litigation Masters: We Must Become Ambassadors for the U.S. Patent System Againon May 23, 2022 at 3:22 pm
Speakers on day one of IPWatchdog’s Patent Litigation Masters program acknowledged that it’s easy for patent owners to become frustrated and disconsolate about how far the pendulum has swung away from ...
- Mechanism of gene mutations linked to autism, Alzheimer's found by TAUon May 23, 2022 at 8:49 am
A mechanism that causes autism, schizophrenia, Alzheimer’s and other conditions and is shared by mutations in the genes ADNP and SHANK3 has been unraveled by Tel Aviv University researchers who ...
- AskBio President of Therapeutics Dr. Katherine High receives Award from American Society of Gene and Cell Therapyon May 23, 2022 at 6:41 am
Jerry Mendell Award recognizes Dr. High for her outstanding work to bring cell and gene therapies to patients RESEARCH TRIANGLE PARK, N.C. , May 23, 2022 /PRNewswire/ -- Asklepios ...
- What the PTAB’s CRISPR-Cas9 Decision for Broad Institute Means for Gene Editing Patent Landscapeon May 20, 2022 at 4:15 am
As previously reported here, on February 28, 2022 the Patent Trial and Appeal Board issued a decision in which it awarded inventive priority to the Broad Institute over the University of California on ...
- BioViva Extends Healthy Lifespan Using Gene Therapyon May 19, 2022 at 5:33 am
BioViva’s Patent-Pending Gene Therapies Delivered with a CMV Vector Extended Lifespans Over 40% and Improved Multiple Markers of Health. SEATTLE, May 19, 2022 /PRNewswire/ -- Ag ...
- Illumina eyes its next move after jury hands down $334 million patent infringement verdicton May 14, 2022 at 12:00 am
Delaware federal jury found that Illumina infringed on two patents of Complete Genomics, a U.S. subsidiary of Chinese firm BGI. The San Diego gene sequencing market leader says it will appeal ...
- Evotenix receives patent for gene synthesis methodon May 9, 2022 at 4:35 am
Evotenix has been granted a European patent for its gene synthesis binary assembly method. The patent further strengthens Evotenix’s IP portfolio and is a key milestone in the company’s strategy to ...
- Evonetix Granted Patent for Binary Assembly Method for Gene Synthesison May 9, 2022 at 1:57 am
EVONETIX LTD (‘Evonetix’), the synthetic biology company bringing semiconductor technology to DNA synthesis, today announced it has been granted a European patent covering its unique Binary Assembly ...
via Bing News